Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Summary

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution

Timeline

Start

2024-08-05

Primary completion

2024-11-21

Completion

2024-11-21

Outcome

Missed primary endpoint

registry analysis (other test); T4090 0.2% vs Rhopressa®; p = 0.376; Mean Difference (Final Values) -0.49; Mixed Models Analysis NCT06394973 ↗

registry analysis (other test); T4090 0.3% vs Rhopressa®; p = 0.518; Mean Difference (Final Values) -0.36; Mixed Models Analysis NCT06394973 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Kinezodianone R	Unknown	0.2 %	Other
Subject	Kinezodianone R	Unknown	0.3 %	Other
Comparator	Netarsudil	Small molecule	0.02 %	Other

Indications